Elevance Health, Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Elevance Health, Inc. |
| Ticker: | Ticker: ELV |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE:ELV). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On March 2, 2026, Elevance disclosed in a filing with the U.S. Securities and Exchange Commission that it “was notified by the Centers for Medicare & Medicaid Services (‘CMS’) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (‘MA-PD’) plans and suspending certain communication activities to Medicare beneficiaries.” Elevance said that “CMS has indicated that the proposed sanctions relate to alleged noncompliance by the Company with certain Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023” and that “[t]he sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues identified have been satisfactorily addressed.” On this news, the price of Elevance shares declined by $25.93 per share, or approximately 8.1%, from $320.00 per share on February 27, 2026 to close at $294.07 on March 2, 2026.
On March 2, 2026, Elevance disclosed in a filing with the U.S. Securities and Exchange Commission that it “was notified by the Centers for Medicare & Medicaid Services (‘CMS’) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (‘MA-PD’) plans and suspending certain communication activities to Medicare beneficiaries.” Elevance said that “CMS has indicated that the proposed sanctions relate to alleged noncompliance by the Company with certain Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023” and that “[t]he sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues identified have been satisfactorily addressed.” On this news, the price of Elevance shares declined by $25.93 per share, or approximately 8.1%, from $320.00 per share on February 27, 2026 to close at $294.07 on March 2, 2026.